Patents by Inventor Christopher Muller
Christopher Muller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20120190722Abstract: Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.Type: ApplicationFiled: March 30, 2012Publication date: July 26, 2012Applicant: ALLERGAN, INC.Inventors: Christopher A. Muller, Janet K. Cheetham, Teresa H. Kuan
-
Patent number: 8207215Abstract: Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.Type: GrantFiled: October 17, 2007Date of Patent: June 26, 2012Assignee: Allergan, Inc.Inventors: Christopher A. Muller, Janet K. Cheetham, Teresa H. Kuan, David F. Power
-
Patent number: 8008338Abstract: Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.Type: GrantFiled: May 28, 2004Date of Patent: August 30, 2011Assignee: Allergan, Inc.Inventors: Christopher A. Muller, Janet K. Cheetham, Teresa H. Kuan, David F. Power
-
Publication number: 20080146553Abstract: Compositions including a quinolone component in an amount effective as an antibiotic when the composition is placed in a mammalian eye, and a carrier component in an amount effective to act as a carrier for the quinolone component are provided. The present compositions are substantially free of other components effective as preservatives. Preferably the quinolone component has fungistatic activity. In one very useful embodiment, the compositions include a NSAID component in an amount effective to reduce inflammation or pain when the composition is placed in a mammalian eye. Methods of using the present compositions, for example, to resolve microbial infections and/or to reduce inflammation and/or pain in a mammalian eye are included within the scope of the present invention.Type: ApplicationFiled: February 20, 2008Publication date: June 19, 2008Applicant: Allergan, Inc.Inventors: Christopher A. Muller, Elizabeth A. Bancroft, Janet K. Cheetham, Harold G. Jensen, Teresa H. Kuan, David F. Power, Kevin D. Skule
-
Publication number: 20080070908Abstract: Compositions including a quinolone component, such as ofloxacin, having fungistatic activity in the compositions, present in an amount effective as an antibiotic when the composition is placed in a mammalian eye, a NSAID component present in an amount to reduce inflammation or pain when the composition is placed in the eye, and a carrier component in an amount effective to act as a carrier for the quinolone component and NSAID component are provided. Methods of using the present compositions, for example, to resolve microbial infections and/or to reduce inflammation and/or pain in a mammalian eye are included within the scope of the present invention. Methods for treating corneal injuries are also included. In addition, methods for treating ocular infections, for example, corneal infections, are included.Type: ApplicationFiled: September 13, 2007Publication date: March 20, 2008Applicant: Allergan, Inc.Inventors: Christopher Muller, Elizabeth Bancroft, Janet Cheetham, Harold Jensen, Teresa Kuan, David Power, Kevin Skule
-
Publication number: 20080027120Abstract: Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.Type: ApplicationFiled: October 17, 2007Publication date: January 31, 2008Inventors: Christopher Muller, Janet Cheetham, Teresa Kuan, David Power
-
Publication number: 20050235888Abstract: A pivot mounting apparatus 210 is provided for pivotally mounting to one another the coal nozzle tip 212 and coal nozzle body 214 of a pulverized solid fuel nozzle 208 of a pulverized solid fuel-fired furnace 10. The pivot mounting apparatus 210 includes a latch interconnecting assembly 220 that includes a pin 222 for insertion in a traversing movement through an insertion passage 224 which passes through both the through hole 216 of the coal nozzle tip 212 and the through hole 218 of the coal nozzle body 214 upon the mutually facing positioning of respective sides of the coal nozzle tip 212 and the coal nozzle body 214 with one another with their respective through holes 216, 218 both co-axial with an insertion axis IAX.Type: ApplicationFiled: April 22, 2004Publication date: October 27, 2005Inventors: Jeffrey Mann, Christopher Muller, Ronald Nowak
-
Publication number: 20050040103Abstract: Enhanced wastewater treatment utilizing directed energy to promote degradation of sludge is disclosed. The directed energy is delivered in a stream circulating to and from an anaerobic digester. The directed energy incorporates mechanical shear energy, ultrasonic energy, and/or hydraulic shear energy. Characterization of odor potential is further disclosed involving the analyzing volatilized sulfur-containing species from dewatered sludge. The odor potential can be used to control operation of the wastewater treatment by controlling the directed energy and/or polymer dose.Type: ApplicationFiled: July 28, 2004Publication date: February 24, 2005Inventors: Mohammad Abu-Orf, Charles Blumenschein, John Novak, Christopher Muller, Mark Laquidara
-
Publication number: 20040248962Abstract: Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.Type: ApplicationFiled: May 28, 2004Publication date: December 9, 2004Applicant: ALLERGAN, INC.Inventors: Christopher A. Muller, Janet K. Cheetham, Teresa H. Kuan, David F. Power
-
Publication number: 20030114464Abstract: Compositions including a quinolone component, such as ofloxacin, having fungistatic activity in the compositions, present in an amount effective as an antibiotic when the composition is placed in a mammalian eye, a NSAID component present in an amount to reduce inflammation or pain when the composition is placed in the eye, and a carrier component in an amount effective to act as a carrier for the quinolone component and NSAID component are provided. Methods of using the present compositions, for example, to resolve microbial infections and/or to reduce inflammation and/or pain in a mammalian eye are included within the scope of the present invention. Methods for treating corneal injuries are also included. In addition, methods for treating ocular infections, for example, corneal infections, are included.Type: ApplicationFiled: September 6, 2002Publication date: June 19, 2003Applicant: Allergan Sales, Inc.Inventors: Christopher A. Muller, Elizabeth A. Bancroft, Janet K. Cheetham, Harold G. Jensen, Teresa H. Kuan, David F. Power, Kevin D. Skule
-
Patent number: 6552020Abstract: Compositions including a quinolone component, such as ofloxacin, having fungistatic activity in the compositions, present in an amount effective as an antibiotic when the composition is placed in a mammalian eye, a NSAID component present in an amount to reduce inflammation or pain when the composition is placed in the eye, and a carrier component in an amount effective to act as a carrier for the quinolone component and NSAID component are provided. Methods of using the present compositions, for example, to resolve microbial infections and/or to reduce inflammation and/or pain in a mammalian eye are included within the scope of the present invention. Methods for treating corneal injuries are also included. In addition, methods for treating ocular infections, for example, corneal infections, are included.Type: GrantFiled: July 24, 2000Date of Patent: April 22, 2003Assignee: Allergan, Inc.Inventors: Christopher A. Muller, Elizabeth A. Bancroft, Janet K. Cheetham, Harold G. Jensen, Teresa H. Kuan, David F. Power, Kevin D. Skule
-
Publication number: 20030073694Abstract: Compositions including a quinolone component in an amount effective as an antibiotic when the composition is placed in a mammalian eye, and a carrier component in an amount effective to act as a carrier for the quinolone component are provided. The present compositions are substantially free of other components effective as preservatives. Preferably the quinolone component has fungistatic activity. In one very useful embodiment, the compositions include a NSAID component in an amount effective to reduce inflammation or pain when the composition is placed in a mammalian eye. Methods of using the present compositions, for example, to resolve microbial infections and/or to reduce inflammation and/or pain in a mammalian eye are included within the scope of the present invention.Type: ApplicationFiled: July 12, 2002Publication date: April 17, 2003Applicant: Allergan Sales, Inc.Inventors: Christopher A. Muller, Elizabeth A. Bancroft, Janet K. Cheetham, Harold G. Jensen, Teresa H. Kuan, David F. Power, Kevin D. Skule
-
Patent number: 6548497Abstract: Methods for reducing non-inflammatory pain caused by injuries and traumas include administering to a mammal eye having non-inflammatory pain a therapeutically effective amount of a composition comprising a quinolone component in an amount effective as an antibiotic and a NSAID component in an amount effective, in combination with the quinolone component, to provide a reduction in non-inflammatory pain.Type: GrantFiled: April 19, 2001Date of Patent: April 15, 2003Assignee: Allergan Sales, Inc.Inventors: Janet K. Cheetham, Harold G. Jensen, Christopher A. Muller, David F. Power, Kevin D. Skule
-
Patent number: 6492361Abstract: Compositions including a quinolone component in an amount effective as an antibiotic when the composition is placed in a mammalian eye, and a carrier component in an amount effective to act as a carrier for the quinolone component are provided. The present compositions are substantially free of other components effective as preservatives. Preferably the quinolone component has fungistatic activity. In one very useful embodiment, the compositions include a NSAID component in an amount effective to reduce inflammation or pain when the composition is placed in a mammalian eye. Methods of using the present compositions, for example, to resolve microbial infections and/or to reduce inflammation and/or pain in a mammalian eye are included within the scope of the present invention.Type: GrantFiled: October 5, 2000Date of Patent: December 10, 2002Assignee: Allergan Sales, IncInventors: Christopher A. Muller, Elizabeth A. Bancroft, Janet K. Cheetham, Harold G. Jensen, Teresa H. Kuan, David F. Power, Kevin D. Skule
-
Publication number: 20010034353Abstract: Methods for reducing non-inflammatory pain caused by injuries and traumas include administering to a mammal eye having non-inflammatory pain a therapeutically effective amount of a composition comprising a quinolone component in an amount effective as an antibiotic and a NSAID component in an amount effective, in combination with the quinolone component, to provide a reduction in non-inflammatory pain.Type: ApplicationFiled: April 19, 2001Publication date: October 25, 2001Applicant: Allergan Sales, Inc.,Inventors: Janet K. Cheetham, Harold G. Jensen, Christopher A. Muller, David F. Power, Kevin D. Skule
-
Patent number: 6166012Abstract: Compositions including a quinolone component in an amount effective as an antibiotic when the composition is placed in a mammalian eye, and a carrier component in an amount effective to act as a carrier for the quinolone component are provided. The present compositions are substantially free of other components effective as preservatives. Preferably the quinolone component has fungistatic activity. In one very useful embodiment, the compositions include a NSAID component in an amount effective to reduce inflammation or pain when the composition is placed in a mammalian eye. Methods of using the present compositions, for example, to resolve microbial infections and/or to reduce inflammation and/or pain in a mammalian eye are included within the scope of the present invention.Type: GrantFiled: July 30, 1999Date of Patent: December 26, 2000Assignee: Allergan Sales, Inc.Inventors: Christopher A. Muller, Elizabeth A. Bancroft, Janet K. Cheetham, Harold G. Jensen, Teresa H. Kuan, David F. Power, Kevin D. Skule